Literature DB >> 24103837

Is quantitative benefit-risk modelling of drugs desirable or possible?

.   

Abstract

Year:  2011        PMID： 24103837     DOI： 10.1016/j.ddtec.2011.03.001

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN： 1740-6749


× No keyword cloud information.
  11 in total

1.  Good decision making requires good communication.

Authors:  Baruch Fischhoff
Journal:  Drug Saf       Date:  2012-11-01       Impact factor: 5.606

Review 2.  Orphan drugs policies: a suitable case for treatment.

Authors:  Michael Drummond; Adrian Towse
Journal:  Eur J Health Econ       Date:  2014-05

Review 3.  A review and classification of approaches for dealing with uncertainty in multi-criteria decision analysis for healthcare decisions.

Authors:  Henk Broekhuizen; Catharina G M Groothuis-Oudshoorn; Janine A van Til; J Marjan Hummel; Maarten J IJzerman
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

Review 4.  Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.

Authors:  Aris Angelis; Ansgar Lange; Panos Kanavos
Journal:  Eur J Health Econ       Date:  2017-03-16

5.  Clinical Knowledge Supported Acute Kidney Injury (AKI) Risk Assessment Model for Elderly Patients.

Authors:  Kao-Yi Shen; Yen-Ching Chuang; Tao-Hsin Tung
Journal:  Int J Environ Res Public Health       Date:  2021-02-08       Impact factor: 3.390

6.  Utilising benefit-risk assessments within clinical trials-a protocol for the BRAINS project.

Authors:  Nikki Totton; Steven Julious; Dyfrig Hughes; Jonathan Cook; Katie Biggs; Lizzie Coates; Andrew Cook; Catherine Hewitt; Simon Day
Journal:  Trials       Date:  2021-01-19       Impact factor: 2.279

7.  Multi-Criteria Decision Analysis for Benefit-Risk Analysis by National Regulatory Authorities.

Authors:  Orin Chisholm; Patrick Sharry; Lawrence Phillips
Journal:  Front Med (Lausanne)       Date:  2022-01-12

8.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153

9.  Approaches to identifying, measuring, and aggregating elements of value.

Authors:  Adrian Towse; Paul Barnsley
Journal:  Int J Technol Assess Health Care       Date:  2013-10       Impact factor: 2.188

10.  Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis.

Authors:  Aris Angelis; Mark Thursz; Vlad Ratziu; Alastair O'Brien; Lawrence Serfaty; Ali Canbay; Ingolf Schiefke; Joao Bana E Costa; Pascal Lecomte; Panos Kanavos
Journal:  Med Decis Making       Date:  2020-08       Impact factor: 2.583
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.